Similarly, PT also exerted significant growth inhibition against 2 independent human cancer xenograft models having different metabolic backgrounds (melanoma, A2058 with complete glycolytic activity; neuroblastoma, NB-1 with deletion of a glycolytic enzyme, PGD; Figure 8, E and F). Here, PGD is linked to melanoma.